A detailed history of Nomura Asset Management CO LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Nomura Asset Management CO LTD holds 485,609 shares of BMRN stock, worth $30.8 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
485,609
Previous 374,926 29.52%
Holding current value
$30.8 Million
Previous $30.9 Million 10.58%
% of portfolio
0.11%
Previous 0.11%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$69.02 - $93.84 $7.64 Million - $10.4 Million
110,683 Added 29.52%
485,609 $34.1 Million
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $4.6 Million - $5.7 Million
-61,829 Reduced 14.16%
374,926 $30.9 Million
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $4.94 Million - $5.84 Million
58,984 Added 15.61%
436,755 $38.1 Million
Q4 2023

Feb 09, 2024

SELL
$76.22 - $98.51 $329,499 - $425,858
-4,323 Reduced 1.13%
377,771 $36.4 Million
Q3 2023

Nov 03, 2023

BUY
$85.07 - $94.48 $7.83 Million - $8.7 Million
92,045 Added 31.73%
382,094 $33.8 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $6.01 Million - $6.95 Million
69,328 Added 31.41%
290,049 $25.1 Million
Q1 2023

May 11, 2023

BUY
$87.74 - $117.27 $10.9 Million - $14.6 Million
124,701 Added 129.87%
220,721 $21.5 Million
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $632,467 - $848,943
-7,815 Reduced 7.53%
96,020 $9.94 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $466,258 - $550,134
5,675 Added 5.78%
103,835 $8.8 Million
Q2 2022

Aug 12, 2022

BUY
$71.48 - $86.85 $499,645 - $607,081
6,990 Added 7.67%
98,160 $8.13 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $136,080 - $169,808
1,832 Added 2.05%
91,170 $7.03 Million
Q4 2021

Feb 01, 2022

BUY
$71.72 - $91.47 $831,952 - $1.06 Million
11,600 Added 14.92%
89,338 $7.89 Million
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $386,635 - $441,965
-5,171 Reduced 6.24%
77,738 $6.01 Million
Q2 2021

Aug 06, 2021

SELL
$75.51 - $84.79 $7.28 Million - $8.17 Million
-96,361 Reduced 53.75%
82,909 $6.92 Million
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $665,097 - $807,141
8,900 Added 5.22%
179,270 $13.5 Million
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $15.1 Million - $18.8 Million
-208,110 Reduced 54.99%
170,370 $14.9 Million
Q3 2020

Nov 12, 2020

BUY
$71.87 - $131.03 $8.18 Million - $14.9 Million
113,808 Added 43.0%
378,480 $28.8 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $14.7 Million - $22.9 Million
184,647 Added 230.74%
264,672 $32.6 Million
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $142,954 - $193,990
2,003 Added 2.57%
80,025 $6.76 Million
Q4 2019

Feb 13, 2020

BUY
$64.27 - $86.37 $449 - $604
7 Added 0.01%
78,022 $6.6 Million
Q3 2019

Nov 13, 2019

BUY
$67.4 - $85.11 $169,645 - $214,221
2,517 Added 3.33%
78,015 $5.26 Million
Q2 2019

Aug 13, 2019

SELL
$80.35 - $93.9 $16,069 - $18,780
-200 Reduced 0.26%
75,498 $6.47 Million
Q1 2019

May 10, 2019

SELL
$84.2 - $98.62 $601,272 - $704,245
-7,141 Reduced 8.62%
75,698 $6.72 Million
Q4 2018

Feb 12, 2019

SELL
$80.14 - $106.07 $63,711 - $84,325
-795 Reduced 0.95%
82,839 $7.05 Million
Q3 2018

Nov 07, 2018

SELL
$93.92 - $105.72 $3.23 Million - $3.64 Million
-34,384 Reduced 29.13%
83,634 $8.11 Million
Q2 2018

Aug 03, 2018

BUY
$76.01 - $99.03 $340,372 - $443,456
4,478 Added 3.94%
118,018 $11.1 Million
Q1 2018

May 14, 2018

BUY
$77.67 - $92.63 $445,282 - $531,047
5,733 Added 5.32%
113,540 $9.21 Million
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $397,904 - $468,705
4,927 Added 4.79%
107,807 $9.61 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $591,362 - $696,648
7,337 Added 7.68%
102,880 $9.57 Million
Q2 2017

Aug 14, 2017

BUY
N/A
95,543
95,543 $8.68 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.